Last updated: September 10, 2026
Poractant alfa, marketed as Curosurf by Chiesi Farmaceutici, is one of the leading exogenous pulmonary surfactants for neonatal respiratory distress syndrome. Its commercial position is supported by broad neonatal intensive-care use, clinical familiarity, and a complex animal-derived composition that limits straightforward generic substitution. The product has no publicly disclosed standalone revenue, and Chiesi reports financial results at group and business-area levels rather than by Curosurf.
Curosurf's growth profile is mature in the United States and Western Europe but remains supported by neonatal intensive-care demand, geographic expansion, and treatment penetration in emerging markets. The principal risks are pricing pressure, hospital purchasing consolidation, alternative surfactants, changes in neonatal respiratory protocols, and the absence of strong product-level disclosure that would allow investors to isolate its contribution to Chiesi's earnings.
What is poractant alfa and how is Curosurf used?
Poractant alfa is a natural pulmonary surfactant extracted from porcine lungs. It contains phospholipids, primarily dipalmitoylphosphatidylcholine, together with surfactant-associated proteins and other lipids. The product is administered intratracheally to premature infants with respiratory distress syndrome and is also used prophylactically or as rescue therapy in selected neonatal settings.
In the United States, Curosurf is supplied as a sterile suspension in 1.5 mL/kg and 3.0 mL/kg initial-dose presentations. The FDA label permits an initial dose of 2.5 mL/kg, equivalent to 200 mg phospholipids/kg, with additional doses of 1.25 mL/kg when clinically indicated. The labeled population is premature infants at risk of, or experiencing, respiratory distress syndrome. Administration requires endotracheal access and trained neonatal staff, which limits dispensing through ordinary retail channels (U.S. Food and Drug Administration, 2024).
Which company markets poractant alfa?
Chiesi Farmaceutici is the originator and global commercial sponsor of Curosurf. Chiesi is a privately held Italian pharmaceutical company with operations in respiratory, rare diseases, neonatology, and specialty care. The company does not disclose Curosurf sales as a separate line item in its public financial reporting.
Chiesi reported group revenue of approximately €3 billion in 2023, with growth driven by a portfolio that includes respiratory products, rare-disease medicines, and specialty hospital products. Curosurf is commercially important within Chiesi's neonatal and hospital portfolio, but its exact revenue, margin, and regional contribution are not separately reported (Chiesi Farmaceutici, 2024).
How large is the poractant alfa and neonatal surfactant market?
Published market estimates vary because analysts define the market differently. Some reports cover all neonatal respiratory distress products, while others include only exogenous surfactants or combine neonatal ventilation and respiratory support technologies. Most third-party estimates place the global neonatal surfactant market in the low-single-digit billions of U.S. dollars, with mid-single-digit annual growth forecasts through the end of the decade.
The commercial market is shaped by four variables:
- The number of premature and low-birth-weight births.
- Surfactant-treatment rates in neonatal intensive-care units.
- Product selection and dosing protocols.
- Access to neonatal intensive-care infrastructure and reimbursement.
The World Health Organization estimates that about 13.4 million babies were born preterm in 2020, representing roughly one in 10 live births worldwide. Preterm birth is the principal demand driver for pulmonary surfactants, although not every premature infant receives exogenous surfactant (World Health Organization, 2023).
What drives demand for Curosurf?
Curosurf demand is strongest in countries with high levels of neonatal intensive-care capacity and established surfactant protocols. The United States, Western Europe, Japan, China, and other developed Asian markets represent the most commercially attractive regions.
Demand is also affected by changes in clinical practice:
- Earlier use of continuous positive airway pressure can reduce the number of infants receiving intubation-based surfactant administration.
- Less-invasive surfactant administration can expand use in infants who avoid prolonged mechanical ventilation.
- Prophylactic use has declined in some settings in favor of early rescue treatment.
- Higher survival rates among extremely premature infants can increase the number of infants requiring respiratory support.
- Hospital formularies often favor products with established handling, dosing, and outcome data.
The product's 200 mg/kg initial dose is commercially relevant because it can reduce the number of vials required for some infants compared with lower-concentration or lower-dose alternatives. Dosing economics depend on infant weight, vial size, wastage, and hospital purchasing agreements.
How does poractant alfa compare with competing surfactants?
Curosurf competes with both animal-derived and synthetic pulmonary surfactants. The principal U.S. competitors include beractant, marketed as Survanta by AbbVie, and calfactant, marketed as Infasurf by Bausch Health and associated commercial partners. Synthetic or protein-containing surfactants have been evaluated in clinical development, but they have not displaced the established animal-derived products across the global market.
| Product |
Active material |
Source |
Initial labeled dose or common use |
Commercial position |
| Curosurf |
Poractant alfa |
Porcine lung extract |
200 mg/kg in the U.S. label |
Major global product marketed by Chiesi |
| Survanta |
Beractant |
Bovine lung extract |
100 mg/kg |
Established competitor with lower initial phospholipid dose |
| Infasurf |
Calfactant |
Calf lung extract |
105 mg/kg |
U.S.-focused competitor |
| Synthetic surfactants |
Variable |
Synthetic or recombinant components |
Product-specific |
Development and regional competition |
Clinical comparisons have generally focused on mortality, need for repeat dosing, air-leak syndromes, oxygenation, and ventilator outcomes. Some studies and meta-analyses have reported advantages for poractant alfa over beractant in selected dosing and clinical contexts, but treatment outcomes are highly dependent on gestational age, timing, ventilation strategy, and neonatal-unit protocols (Moya et al., 2019).
Curosurf's commercial advantage is therefore based on the combination of clinical familiarity, high-concentration dosing, global distribution, and physician experience rather than on a legally protected monopoly.
What is the FDA regulatory status of Curosurf?
The FDA approved Curosurf in 1999 under New Drug Application 20-614 for prevention and treatment of respiratory distress syndrome in premature infants. The product is a prescription biological drug administered in a hospital or neonatal-care setting.
Curosurf's regulatory status has several commercial implications:
- It is supplied through institutional channels rather than ordinary retail pharmacies.
- Its use depends on neonatal intensive-care capacity.
- Purchasing decisions are made by hospitals, health systems, government programs, and group purchasing organizations.
- Product handling and administration requirements create operational barriers to rapid substitution.
- The product is not a self-administered biologic and does not have the commercial dynamics of outpatient injectable medicines.
The FDA label does not create a continuing market exclusivity period comparable to a recently approved orphan or pediatric product. The product's current commercial protection comes primarily from manufacturing capability, clinical adoption, brand recognition, and market access.
What patents protect poractant alfa and when does Curosurf lose exclusivity?
Curosurf's original composition and product patents are expected to be expired or commercially exhausted in the United States and major European markets. The original U.S. approval dates from 1999, making the product too old to retain ordinary small-molecule-style patent exclusivity based solely on the original approval.
The relevant protection is more likely to involve:
- Manufacturing and purification processes.
- Composition specifications for porcine lung extract.
- Formulation stability.
- Vial and suspension characteristics.
- Administration methods or neonatal treatment protocols.
- Brand, regulatory, and trade-secret protection.
Patent ownership and expiration cannot be assessed reliably from the product name alone because patent families differ by jurisdiction and may cover manufacturing steps rather than the approved product itself. Public Orange Book information should be reviewed for any active listed patents associated with the current NDA. Patent expiry, however, is not the main barrier to entry for this product class.
Why has generic or biosimilar substitution been limited?
Poractant alfa is a complex biological mixture rather than a single chemically defined active ingredient. A prospective competitor must demonstrate consistent source material, extraction, purification, lipid composition, protein content, sterility, potency, and clinical performance.
The regulatory pathway is also less straightforward than for a conventional generic tablet. A competing product may require a full or abbreviated biological development strategy, depending on FDA classification and the extent to which equivalence can be established. Even after approval, automatic pharmacy substitution is unlikely to be the primary commercial mechanism because administration occurs in hospitals and neonatal units.
No FDA-approved interchangeable biosimilar substitute for Curosurf is broadly recognized in the U.S. market. This does not eliminate competitive risk. A competing surfactant could enter through an independent biologic or drug approval pathway and win formulary share without being interchangeable.
Are there Paragraph IV challenges or Curosurf patent lawsuits?
No major, publicly established Paragraph IV litigation campaign against Curosurf has reshaped the U.S. market in the manner seen for high-value outpatient drugs. The absence of high-profile litigation is consistent with the product's older patent estate, complex biological composition, and hospital-administered market.
A future challenger could still contest process, formulation, or method-of-use patents. The commercial value of such litigation would depend on whether the patent blocked a viable competing surfactant, not merely whether it covered a narrow manufacturing step.
What litigation risks matter most?
The more material risks are likely to involve:
- Product liability relating to neonatal outcomes or administration errors.
- Manufacturing deviations or contamination.
- Supply interruptions involving porcine raw material.
- Regulatory disputes over comparability or biologic classification.
- Hospital-contract disputes and pricing practices.
- Intellectual-property disputes over extraction, purification, and formulation methods.
Publicly available information does not establish a current litigation event that materially threatens Curosurf's global commercial position.
What is the financial trajectory for poractant alfa?
Curosurf's financial trajectory is likely mature but durable. The product has several characteristics associated with stable specialty-hospital revenue:
- Chronic clinical need tied to premature birth.
- High physician familiarity.
- Limited outpatient substitution.
- Complex production requirements.
- Repeat-dose use in a subset of infants.
- Institutional purchasing that favors reliable supply.
Growth is likely to come from volume and geographic penetration rather than substantial price increases. In the United States and Western Europe, pricing pressure can arise from hospital tenders, group purchasing organizations, and competing surfactants. Emerging-market growth depends on neonatal-unit expansion, reimbursement, and the availability of trained staff.
| Financial driver |
Directional impact on Curosurf |
Rationale |
| Preterm birth volume |
Positive |
Expands the underlying treatment population |
| Neonatal intensive-care expansion |
Positive |
Increases diagnosis and treatment capacity |
| Less-invasive surfactant administration |
Mixed to positive |
Can reduce intubation while preserving surfactant use |
| Hospital tendering |
Negative for price, neutral for volume |
Increases purchasing pressure |
| Generic or biosimilar entry |
Potentially negative |
Could lower price or displace formulary share |
| Manufacturing complexity |
Positive for incumbent |
Raises barriers to reliable competition |
| Porcine-source supply disruption |
Negative |
Could constrain production or increase cost |
| Clinical preference for competing surfactants |
Negative |
Can reduce institutional share |
Chiesi's total revenue growth should not be treated as a direct proxy for Curosurf growth. The group has diversified into rare diseases, respiratory medicines, specialty products, and licensing transactions. A rising corporate revenue figure can coexist with stable or declining Curosurf sales.
What licensing deals affect the poractant alfa market?
Curosurf has historically been supported by Chiesi's own commercial infrastructure and regional distribution arrangements. Public disclosure does not provide a comprehensive product-level schedule of all licensing, co-promotion, or distribution agreements.
Licensing risk is lower than for a development-stage biologic because Curosurf is already approved and commercially established. The more relevant commercial question is whether Chiesi expands through regional distribution partners in markets where it lacks direct hospital coverage. Such arrangements can accelerate access but may reduce net realized revenue through partner discounts and royalties.
No disclosed transaction currently indicates a transfer of global Curosurf control or a restructuring that would materially alter the product's ownership profile.
What generic launch scenarios exist for Curosurf?
Three scenarios are commercially plausible.
Scenario 1: Continued branded durability
Curosurf remains the preferred or co-preferred product in major neonatal markets. Revenue grows at a low-single-digit rate through volume, new neonatal capacity, and stable clinical use. Price growth remains limited.
Scenario 2: Regional competitor entry
A competing porcine or bovine surfactant gains approval in selected markets. Chiesi retains the leading position but faces tender discounts and reduced share in price-sensitive hospitals.
Scenario 3: Broader biologic competition
A product with comparable clinical performance and reliable supply obtains approval in major markets. Curosurf experiences formulary displacement, lower net pricing, and higher contracting costs. This scenario would have the greatest impact on operating margin.
A rapid, nationwide generic erosion event is less likely than gradual hospital-level share migration because surfactant use is physician-administered and institutionally purchased.
How strong is the poractant alfa patent and commercial estate?
The patent estate is likely moderate to weak in classic exclusivity terms but stronger in practical barriers to entry. The product's original approval age reduces the value of core composition patents. Manufacturing know-how, source-material controls, quality systems, clinical familiarity, and hospital relationships remain commercially significant.
| Protection category |
Estimated strength |
| Original composition patents |
Low after long market tenure |
| Formulation and stability patents |
Low to moderate, depending on jurisdiction |
| Manufacturing know-how |
Moderate to high |
| Regulatory experience |
High |
| Physician and hospital familiarity |
High |
| Automatic substitution protection |
Moderate because of hospital administration |
| Brand value |
Moderate to high |
| Supply-chain capability |
High relative to potential entrants |
Geographic protection is uneven. U.S. and European patent rights are likely largely expired, while later process or formulation rights may remain in individual jurisdictions. Market access, regulatory approval, and local manufacturing standards can matter more than patent duration in lower-income countries.
What is the outlook for poractant alfa revenue?
The base-case outlook is for stable to modest growth, not a high-growth pharmaceutical trajectory. The product should continue generating recurring hospital revenue while maintaining strategic value within Chiesi's neonatal portfolio.
A reasonable commercial assessment is:
- Mature developed markets: flat to low-single-digit growth.
- China and selected emerging markets: higher unit growth from expanding neonatal care.
- Net pricing: flat or pressured.
- Gross margin: structurally attractive but exposed to manufacturing and supply-chain costs.
- Competitive risk: gradual rather than sudden.
- Revenue visibility: good at the product-class level but limited at the company-reporting level.
Investors should not assign a precise Curosurf revenue estimate from Chiesi's consolidated results. The company does not report enough product-level information to calculate standalone sales, regional profitability, or contribution to group earnings without proprietary market data.
Key Takeaways
- Poractant alfa, marketed as Curosurf, is a leading porcine-derived pulmonary surfactant for premature infants with neonatal respiratory distress syndrome.
- Chiesi owns and markets the product globally, but it does not disclose standalone Curosurf revenue.
- The product's financial profile is mature, recurring, and hospital-focused, with volume growth offset by tender and reimbursement pressure.
- Original product patents are likely expired or commercially exhausted in major markets.
- Manufacturing complexity, regulatory requirements, clinical familiarity, and hospital purchasing relationships create meaningful practical barriers to entry.
- No major public Paragraph IV campaign or biosimilar launch currently defines the U.S. market.
- The main financial risk is gradual formulary and pricing erosion from competing surfactants, not an immediate patent cliff.
- Revenue growth is most likely to come from neonatal intensive-care expansion and geographic penetration rather than price increases.
FAQs
Is poractant alfa a biologic drug?
Yes. Poractant alfa is a biological pulmonary surfactant derived from porcine lung tissue. Its complex mixture of phospholipids and proteins makes direct generic replication more difficult than replication of a chemically defined active ingredient.
Is Curosurf interchangeable with Survanta?
No automatic assumption of interchangeability should be made. Curosurf and Survanta contain different animal-derived surfactant materials, have different concentrations and dosing regimens, and are selected according to hospital protocols and physician judgment.
Does Curosurf have orphan-drug exclusivity?
Curosurf's commercial position does not depend on a current orphan-drug exclusivity period. Its U.S. approval dates to 1999, and any original regulatory exclusivity would have expired long ago.
Can poractant alfa be administered without mechanical ventilation?
Less-invasive surfactant administration techniques can deliver surfactant to spontaneously breathing infants in selected clinical settings. The specific method depends on neonatal-unit expertise, equipment, and the treating physician's protocol.
What would most improve Curosurf's financial trajectory?
The strongest growth levers are wider access to neonatal intensive care, increased use in emerging markets, adoption of less-invasive administration, and continued preference for high-concentration poractant alfa. Price increases are a less reliable growth source because hospital procurement systems exert substantial pressure on net pricing.
References
-
Chiesi Farmaceutici. (2024). Annual report and consolidated financial statements 2023. Chiesi Farmaceutici S.p.A.
-
Moya, F. R., Sinha, S., Gadzinowski, J., D’Agostino, R., Segal, R., Haddad, B., & Cheng, S. (2019). One-year follow-up of very preterm infants who received poractant alfa or beractant for respiratory distress syndrome. Journal of Perinatology, 39(8), 1100-1108.
-
U.S. Food and Drug Administration. (2024). Curosurf (poractant alfa) prescribing information. FDA.
-
World Health Organization. (2023). Preterm birth. WHO.
